2025
Assessing the impact of revising MenACWY vaccination schedule for adolescents in the United States: a modelling study
Shoukat A, Wells C, Shin T, Potter-Schwartz L, Galvani A, Moghadas S. Assessing the impact of revising MenACWY vaccination schedule for adolescents in the United States: a modelling study. The Lancet Regional Health - Americas 2025, 44: 101033. PMID: 40046840, PMCID: PMC11880592, DOI: 10.1016/j.lana.2025.101033.Peer-Reviewed Original ResearchInvasive meningococcal diseaseInvasive meningococcal disease casesVaccination scheduleVaccine uptakeAlternative schedulesMenACWY vaccination programCase fatality rateHigh-risk adolescentsVaccine introductionBooster doseIMD casesSerogroup CCompare outcomesMenACWY vaccineAsymptomatic infectionImmunization PracticesMeningococcal diseaseVaccine effectivenessIMD incidenceDoseSerogroups AVaccineStudy periodVaccination programIncrease vaccine uptake
2024
Impact of rotavirus vaccination in Malawi from 2012 to 2022 compared to model predictions
Pitzer V, Ndeketa L, Asare E, Hungerford D, Lopman B, Jere K, Cunliffe N. Impact of rotavirus vaccination in Malawi from 2012 to 2022 compared to model predictions. Npj Vaccines 2024, 9: 227. PMID: 39562592, PMCID: PMC11576906, DOI: 10.1038/s41541-024-01008-6.Peer-Reviewed Original ResearchRotavirus-associated gastroenteritisRotavirus-negative childrenRotavirus-negative controlsImpact of rotavirus vaccinationVaccination coverageRotavirus vaccine impactAcute gastroenteritis casesNational immunization programPre-vaccination dataVaccine introductionRotavirus vaccineVaccine impactAcute gastroenteritisVaccine effectivenessGastroenteritis casesLow-income settingsImmunization programsVaccineThe public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study
Schmit N, Topazian H, Natama H, Bellamy D, Traoré O, Somé M, Rouamba T, Tahita M, Bonko M, Sourabié A, Sorgho H, Stockdale L, Provstgaard-Morys S, Aboagye J, Woods D, Rapi K, Datoo M, Lopez F, Charles G, McCain K, Ouedraogo J, Hamaluba M, Olotu A, Dicko A, Tinto H, Hill A, Ewer K, Ghani A, Winskill P. The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study. The Lancet Infectious Diseases 2024, 24: 465-475. PMID: 38342107, DOI: 10.1016/s1473-3099(23)00816-2.Peer-Reviewed Original ResearchDisability-adjusted life yearsClinical malariaMalaria vaccineClinical casesVaccine introductionVaccinated childrenVaccine efficacyYears of follow-upPhase 2b trialPhase 3 trialSub-Saharan AfricaSurrogate of protectionIncremental costAntibody titresPublic health impactSerum Institute of IndiaBill &Cost-effectiveness ratioChildren Aged 2Dose pricesMalaria deathsMelinda Gates FoundationNIHR Oxford Biomedical Research CentreFollow-upUK Medical Research Council
2023
Cost of introducing and delivering malaria vaccine (RTS,S/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso
Diawara H, Bocoum F, Dicko A, Levin A, Lee C, Koita F, Ouédraogo J, Guissou R, Yabré S, Traoré S, Morgan W, Pecenka C, Baral R. Cost of introducing and delivering malaria vaccine (RTS,S/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso. BMJ Global Health 2023, 8: e011316. PMID: 37068848, PMCID: PMC10111920, DOI: 10.1136/bmjgh-2022-011316.Peer-Reviewed Original ResearchConceptsVaccine deliverySeasonal vaccinationMalaria vaccineMalaria transmissionSeasonal malaria transmissionRoutine Expanded ProgrammeResource use dataRoutine EPINew vaccine introductionSeasonal malariaVaccine introductionMain cost driversHealth facilitiesExpanded ProgrammeVaccine priceVaccine rolloutMass campaignsService deliveryYoung childrenVaccinationCost consequencesBurkina FasoFinancial costsVaccineDelivery approach
2022
Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness
Burrows H, Antillón M, Gauld J, Kim J, Mogasale V, Ryckman T, Andrews J, Lo N, Pitzer V. Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness. Vaccine 2022, 41: 965-975. PMID: 36586741, PMCID: PMC9880559, DOI: 10.1016/j.vaccine.2022.12.032.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioRoutine vaccinationVaccine impactPublic health impactOne-time catchPotential public health impactHigh-incidence settingsTyphoid fever casesCost-effectiveness ratioMonths of ageHealth impactsModel-predicted outcomesPrimary outcomeChronic carriersIncidence settingsSymptomatic casesVaccine introductionEndemic settingsVaccine deploymentFever casesVaccinationTyphoid casesIncremental costTyphoid transmissionMonthsTrends in disparities in COVID hospitalizations among community‐dwelling residents of two counties in Connecticut, before and after vaccine introduction, March 2020–September 2021
McWilliams C, Bothwell L, Yousey‐Hindes K, Hadler J. Trends in disparities in COVID hospitalizations among community‐dwelling residents of two counties in Connecticut, before and after vaccine introduction, March 2020–September 2021. Influenza And Other Respiratory Viruses 2022, 17: e13082. PMID: 36509459, PMCID: PMC9835416, DOI: 10.1111/irv.13082.Peer-Reviewed Original ResearchConceptsCOVID-19 hospitalizationNon-Hispanic blacksGeocoded residential addressesAge-adjusted incidenceNon-Hispanic whitesHispanic/LatinxVaccination ratesLaboratory-confirmed COVID-19Residential addressesSocioeconomic statusSurveillance Network databaseCommunity-dwelling residentsNon-institutionalized personsIntroduction of vaccinesLow socioeconomic statusCensus tract measuresRace/ethnicityLower SES groupsVaccine registryVaccine introductionVaccination levelsHospitalizationVaccine rolloutDelta wavesSES disparitiesPredicting the long-term impact of rotavirus vaccination in 112 countries from 2006 to 2034: A transmission modeling analysis
Kraay A, Steele M, Baker J, Hall E, Deshpande A, Saidzosa B, Mukaratirwa A, Boula A, Mpabalwani E, Kiulia N, Tsolenyanu E, Enweronu-Laryea C, Abebe A, Beyene B, Tefera M, Willilo R, Batmunkh N, Pastore R, Mwenda J, Antoni S, Cohen A, Pitzer V, Lopman B. Predicting the long-term impact of rotavirus vaccination in 112 countries from 2006 to 2034: A transmission modeling analysis. Vaccine 2022, 40: 6631-6639. PMID: 36210251, PMCID: PMC10351612, DOI: 10.1016/j.vaccine.2022.09.072.Peer-Reviewed Original ResearchConceptsRotavirus vaccinationRotavirus positivityVaccine introductionOne-dose scheduleTwo-dose seriesRotavirus burdenRotavirus casesRotavirus gastroenteritisHospital admissionMiddle-income countriesVaccine impactVaccinated individualsLong-term impactMortality burdenPercent reductionVaccinationLife yearsIndirect protectionLow-income countriesLong-term magnitudePositivityDeathBurdenYearsIntroduction Data
2021
Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project
Quesada M, Yang Y, Bennett JC, Hayford K, Zeger SL, Feikin DR, Peterson ME, Cohen AL, Almeida SCG, Ampofo K, Ang M, Bar-Zeev N, Bruce MG, Camilli R, Chacón G, Ciruela P, Cohen C, Corcoran M, Dagan R, De Wals P, Desmet S, Diawara I, Gierke R, Guevara M, Hammitt LL, Hilty M, Ho PL, Jayasinghe S, Kleynhans J, Kristinsson KG, Ladhani SN, McGeer A, Mwenda JM, Nuorti JP, Oishi K, Ricketson LJ, Sanz JC, Savrasova L, Setchanova LP, Smith A, Valentiner-Branth P, Valenzuela MT, van der Linden M, van Sorge NM, Varon E, Winje BA, Yildirim I, Zintgraff J, Knoll MD. Serotype Distribution of Remaining Pneumococcal Meningitis in the Mature PCV10/13 Period: Findings from the PSERENADE Project. Microorganisms 2021, 9: 738. PMID: 33916227, PMCID: PMC8066874, DOI: 10.3390/microorganisms9040738.Peer-Reviewed Original ResearchHigher-valency PCVsPneumococcal meningitisSerotype distributionPneumococcal meningitis incidencePneumococcal serotype replacementAfrican meningitis beltPneumococcal meningitis casesYears of agePCV13 typesSerotype replacementMeningitis casesVaccine introductionMeningitis beltMeningitis incidenceVaccination programInvestigational productMeningitisSerotype 3SerotypesPCVRegression modelsAgeYearsPCV10/13PCV10
2020
Modeling of rotavirus transmission dynamics and impact of vaccination in Ghana
Asare EO, Al-Mamun MA, Armah GE, Lopman BA, Parashar UD, Binka F, Pitzer VE. Modeling of rotavirus transmission dynamics and impact of vaccination in Ghana. Vaccine 2020, 38: 4820-4828. PMID: 32513513, PMCID: PMC8290434, DOI: 10.1016/j.vaccine.2020.05.057.Peer-Reviewed Original ResearchConceptsVaccine response ratesRotavirus vaccine impactRotavirus incidenceVaccine impactMaternal immunityResponse rateVaccine effectivenessLow-income countriesTeaching hospitalHigh-income countriesKorle-Bu Teaching HospitalKomfo Anokye Teaching HospitalMonovalent rotavirus vaccineRotavirus transmission dynamicsLow vaccine effectivenessProportion of infantsImpact of vaccinationWar Memorial HospitalAge distributionRotavirus casesRotavirus vaccineVaccine introductionVaccine performanceMemorial HospitalRotavirus seasonalityEstimating the power to detect a change caused by a vaccine from time series data
Weinberger D, Warren J. Estimating the power to detect a change caused by a vaccine from time series data. Gates Open Research 2020, 4: 27. DOI: 10.12688/gatesopenres.13116.1.Peer-Reviewed Original Research
2019
Assessing sociodemographic differences in human papillomavirus vaccine impact studies in the United States: a systematic review using narrative synthesis
Avni-Singer LR, Yakely A, Sheth SS, Shapiro ED, Niccolai LM, Oliveira CR. Assessing sociodemographic differences in human papillomavirus vaccine impact studies in the United States: a systematic review using narrative synthesis. Public Health 2019, 178: 137-150. PMID: 31698136, PMCID: PMC6994345, DOI: 10.1016/j.puhe.2019.08.010.Peer-Reviewed Original ResearchConceptsHPV vaccineVaccine impact studiesSociodemographic disparitiesSystematic reviewImportant public health priorityHPV vaccine eraReduction of HPVPopulation-level burdenPublic health priorityPubMed/MEDLINEScience Citation IndexHPV infectionGenital wartsSocio-economic subgroupsCervical dysplasiaRoutine vaccinationVaccine eraVaccine impactCitation IndexHuman papillomavirusVaccine introductionSentinel surveillanceStudy protocolEligible studiesHealth priority962. Trends in Cervical Pre-cancers by Race and Ethnicity During the Human Papillomavirus Vaccine Era, HPV Vaccine Impact Monitoring Project (HPV-IMPACT), United States, 2008–2016
Gargano J, Lewis R, Hunt H, McClung N, Bennett N, Griffin M, Niccolai L, Park I, Powell M, Brackney M, Scahill M, Pemmaraju M, Fink D, Ehlers S, Cleveland A, Unger E, Markowitz L. 962. Trends in Cervical Pre-cancers by Race and Ethnicity During the Human Papillomavirus Vaccine Era, HPV Vaccine Impact Monitoring Project (HPV-IMPACT), United States, 2008–2016. Open Forum Infectious Diseases 2019, 6: s29-s29. PMCID: PMC6809029, DOI: 10.1093/ofid/ofz359.064.Peer-Reviewed Original ResearchAverage annual percentage changeCervical intraepithelial neoplasiaRace/ethnicityVaccine eraYear oldsNH blacksNH whitesHuman papillomavirus vaccine introductionActive population-based surveillanceHPV vaccine eraPopulation-based surveillanceConfidence intervalsAnnual percentage changeSignificant declineScreened womenVaccine impactRace/ethnicity dataCervical cancerIntraepithelial neoplasiaVaccine introductionCIN2Hispanic womenJoinpoint softwareSitu casesAge groupsHuman papillomavirus vaccination and anogenital warts
Yakely AE, Avni-Singer L, Oliveira CR, Niccolai LM. Human papillomavirus vaccination and anogenital warts. Sexually Transmitted Diseases 2019, Publish Ahead of Print: &na;. PMID: 30461595, PMCID: PMC6640846, DOI: 10.1097/olq.0000000000000948.Peer-Reviewed Original ResearchConceptsAnogenital wartsAge 25 yearsHPV vaccineEffectiveness studiesHPV vaccine impactHuman papillomavirus vaccinationPre-vaccine eraMale vaccinationPapillomavirus vaccinationVaccination historyVaccine impactVaccine introductionFemale vaccinationEmbase databasesVaccination programEligible studiesExclusion criteriaLower riskVaccineVaccinationWartsPrevention potentialReal-world benefitsFemalesUnited States
2018
Direct and possible indirect effects of vaccination on rotavirus hospitalisations among children in Malawi four years after programmatic introduction
Bennett A, Pollock L, Jere K, Pitzer V, Parashar U, Tate J, Heyderman R, Mwansambo C, French N, Nakagomi O, Iturriza-Gomara M, Everett D, Cunliffe N, Bar-Zeev N, Consortium F. Direct and possible indirect effects of vaccination on rotavirus hospitalisations among children in Malawi four years after programmatic introduction. Vaccine 2018, 36: 7142-7148. PMID: 29887320, PMCID: PMC6238204, DOI: 10.1016/j.vaccine.2018.04.030.Peer-Reviewed Original ResearchConceptsPost-vaccine introductionPrevalence of rotavirusVaccine effectivenessRotavirus prevalenceAcute gastroenteritisVaccine introductionRotavirus hospitalisationsVaccine coverageEfficacy estimatesAdjusted vaccine effectivenessRotavirus vaccine introductionYears of ageUse of vaccinesUnvaccinated infantsRotavirus diarrheaRotavirus diseaseUnvaccinated childrenReferral hospitalRoutine immunisationMalawian childrenSevere diarrheaStool samplesImportant causePoisson regressionHospitalisation
2016
In-season and out-of-season variation of rotavirus genotype distribution and age of infection across 12 European countries before the introduction of routine vaccination, 2007/08 to 2012/13.
Hungerford D, Vivancos R, Read J, Pitzer V, Cunliffe N, French N, Iturriza-Gómara M. In-season and out-of-season variation of rotavirus genotype distribution and age of infection across 12 European countries before the introduction of routine vaccination, 2007/08 to 2012/13. Eurosurveillance 2016, 21 PMID: 26794258, DOI: 10.2807/1560-7917.es.2016.21.2.30106.Peer-Reviewed Original ResearchConceptsGenotype distributionMultinomial multivariate logistic regressionRotavirus gastroenteritis casesRotavirus genotype distributionRoutine rotavirus vaccinationRotavirus vaccination programRotavirus-positive specimensMultivariate logistic regressionOdds of infectionAge of infectionRVGE casesUntypable genotypesRotavirus vaccinationRoutine vaccinationVaccine introductionVaccination programGastroenteritis casesEpidemiological changesGenotype surveillanceLogistic regressionCommon genotypeMicrobiological dataVaccinationSurveillance networkAge
2015
Epidemiological Markers for Interactions Among Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Upper Respiratory Tract Carriage
Lewnard JA, Givon-Lavi N, Huppert A, Pettigrew MM, Regev-Yochay G, Dagan R, Weinberger DM. Epidemiological Markers for Interactions Among Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Upper Respiratory Tract Carriage. The Journal Of Infectious Diseases 2015, 213: 1596-1605. PMID: 26704617, PMCID: PMC4837906, DOI: 10.1093/infdis/jiv761.Peer-Reviewed Original ResearchMeSH KeywordsCarrier StateChild, PreschoolFemaleHaemophilus InfectionsHaemophilus influenzaeHeptavalent Pneumococcal Conjugate VaccineHumansInfantIsraelLongitudinal StudiesMalePneumococcal InfectionsRespiratory Tract InfectionsRisk FactorsStaphylococcal InfectionsStaphylococcus aureusStreptococcus pneumoniaeVaccines, ConjugateConceptsPneumococcal serotype replacementH. influenzaeSerotype replacementS. pneumoniaeHaemophilus influenzaeStreptococcus pneumoniaePneumococcal conjugate vaccine trialUpper respiratory tract carriagePneumococcal vaccine introductionS. aureus carriageMonths of ageStaphylococcus aureusPCV7 recipientsAureus carriageVaccine introductionVaccine trialsCarriage patternsConfounding factorsClinical interventionsInfluenzaeEpidemiological markersBedouin childrenPneumoniaeCarriageS. aureusDid Large-Scale Vaccination Drive Changes in the Circulating Rotavirus Population in Belgium?
Pitzer VE, Bilcke J, Heylen E, Crawford FW, Callens M, De Smet F, Van Ranst M, Zeller M, Matthijnssens J. Did Large-Scale Vaccination Drive Changes in the Circulating Rotavirus Population in Belgium? Scientific Reports 2015, 5: 18585. PMID: 26687288, PMCID: PMC4685644, DOI: 10.1038/srep18585.Peer-Reviewed Original ResearchConceptsVaccine introductionStrain-specific vaccine effectivenessVaccine-derived immunityRotavirus vaccine introductionVaccine-induced immunityAbsence of vaccinationRotavirus populationLarge-scale vaccinationDistribution of genotypesRotavirus gastroenteritisVaccine effectivenessHomotypic strainHospitalization dataPredominant rotavirusStrain replacementVaccinationVaccineImmunityInfectionViral populationsPopulationGastroenteritisYearsIncidenceRotavirusMonitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008–2012 - Volume 21, Number 9—September 2015 - Emerging Infectious Diseases journal - CDC
Hariri S, Markowitz LE, Bennett NM, Niccolai LM, Schafer S, Bloch K, Park IU, Scahill MW, Julian P, Abdullah N, Levine D, Whitney E, Unger ER, Steinau M, Bauer HM, Meek J, Hadler J, Sosa L, Powell SE, Johnson ML, Group H. Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008–2012 - Volume 21, Number 9—September 2015 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2015, 21: 1557-1561. PMID: 26291379, PMCID: PMC4550135, DOI: 10.3201/eid2109.141841.Peer-Reviewed Original ResearchConceptsHuman papillomavirus vaccineYears of agePapillomavirus vaccineEmerging Infections Program sitesPopulation-based surveillance systemActive population-based surveillanceInfectious Diseases journal - CDCPre-invasive cervical lesionsHPV vaccination historyHPV type distributionPopulation-based surveillanceCervical intraepithelial neoplasiaAcute infectious diseasesRelevant clinical informationCatchment area populationHPV vaccinationHPV typesVaccination historyIntraepithelial neoplasiaCervical cancerCervical lesionsVaccine introductionWomen 18Clinical informationUS population
2012
<i>Neisseria meningitis</i> serogroup X outbreak in Burkina Faso, 2009-2010
Yaro S, Drabo A, Ouangraoua S, Kirakoya-Samadoulougou F, Mueller J, Sanou O, Tall H, Jaillard P, Njanpop-Lafourcade B, Macq J, Robert A, Ouedraogo J. Neisseria meningitis serogroup X outbreak in Burkina Faso, 2009-2010. Open Journal Of Internal Medicine 2012, 2012: 41-49. DOI: 10.4236/ojim.2012.22010.Peer-Reviewed Original ResearchVaccine introductionPolymerase chain reactionSerogroup XPneumococcal vaccine introductionContacts of patientsReference laboratoryCountries' national guidelinesPilot districtsAdequate antibioticsCentre MurazCampaign vaccinationSecondary casesPolyvalent vaccineSerogroup distributionFluid collectionNational guidelinesVaccine compositionCSF samplesEpidemiological seasonFaster careLaboratory capacityAttack rateChain reactionBobo-DioulassoPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply